Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Blood Levels of Immune Protein… >

Blood Levels of Immune Protein Predict Risk in Hodgkin Disease

Published: December 10, 2012.
Released by Dana-Farber Cancer Institute  

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

In a study of 315 patients from a German database, researchers from Dana-Farber Cancer Institute found that serum galectin-1 levels "are significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."

The measurements were made possible by a new laboratory test called a "sandwich ELISA" devised by the Dana-Farber team, led by Margaret Shipp, MD, director of the lymphoma program at Dana-Farber. Galectin-1 is a protein which, when overexpressed by Hodgkin lymphoma cells, allows them to evade the body's immune response that normally would detect the cancer and attack it with cell-killing lymphocytes. The Shipp group developed antibodies that recognize the galectin-1 protein and were used in developing the sandwich ELISA assay.

Since the protein is secreted into the bloodstream, the investigators hypothesized that measuring relative levels of galectin-1 in newly diagnosed, untreated Hodgkin patients could help to assess likely outcomes in those patients. Such predictions, in turn, could help physicians decide how aggressively to treat the lymphoma, Shipp explained. With further development, she added, the assay could become "an objective test that might help make decisions on which way to treat patients."

The Dana-Farber scientists collaborated with researchers of the German Hodgkin Study Group (GHSG) at the University Hospital of Cologne. Shipp said that the GHSG has "probably the largest, most comprehensive data on clinical trials of patient with well-defined Hodgkin lymphoma." The 315 patients whose blood levels of galactin-1 were tested in the study had been enrolled in three different clinical trials – one for early-stage disease, a second for early-stage disease with additional less-favorable risk factors, and the third for patients with bulky localized or advanced-stage disease.

Using the sandwich ELISA assay, the Dana-Farber investigators found that blood galectin-1 levels in Hodgkin lymphoma patients were significantly higher than in normal control patients. They also found that relative galectin-1 levels were correlated with the risk factors that had been used to assign the 315 patients to the three different clinical trials. Direct comparisons of the galectin-1 levels with patient outcomes are awaiting the completion of one of the clinical trials, the researchers noted.

Beyond the potential for a clinical test, galectin-1 holds promise as a therapeutic target, said Shipp, whose group has made a "neutralizing" antibody to block the protein. She said the antibody, which is produced in mice, would need to be "humanized," or genetically modified to be compatible with human patients, and then undergo rigorous testing for safety and efficacy. This is under discussion with potential industrial partners, said Shipp.




The above story is based on materials provided by Dana-Farber Cancer Institute.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Lymphoma 
3/27/15 
Experts Set Strategic Priorities for Lymphoma Research
(WASHINGTON - March, 26, 2015) - A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority …
Lymphoma 
3/31/13 
Singapore Clinician-scientists Identify New Type of Deadly Lymphoma
Singapore, 31 March 2013 – An international research team has identified a new type of deadly intestinal lymphoma that …
Medicine 
1/30/14 
Geranium Extracts Inhibit HIV-1
Scientists from the Helmholtz Zentrum München demonstrate that root extracts of the medicinal plant Pelargonium sidoides (PS) contain compounds …
Helmholtz 
11/13/12 
Doubling Down Against Diabetes
A collaboration between scientists in Munich, Germany and Bloomington, USA may have overcome one of the major challenges drug …
Ezh2 
11/15/10 
Epizyme Identifies Novel Opportunity for Treatment of Genetically Defined Human B-cell Lymphomas
Cambridge, MA, November 15, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer …
Pdgfrb 
10/15/12 
★★ 
Of Mice And Men
So-called Anaplastic Large Cell Lymphoma (ALCL) is even less attractive in real life than it is on paper. It …
Release 
9/20/13 
Prostacyclin Analogs And PDE 5 Inhibitors Synergistically Stimulate ATP Release from Human RBCs
Researchers at Saint Louis University School of Medicine have discovered a novel interaction between prostacyclin (PGI2) analogs and phosphodiesterase …
Patients 
1/15/15 
Research Offers Novel Insight into Hirschsprung's Disease
Bethesda, MD (Jan. 15, 2015) -- Defects in the protein Sox10, a transcription factor that regulates gene expression, may …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile